cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. It also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. The company distributes its products through its e-commerce Website, third-party e-commerce sites, wholesalers, and various brick and mortar retailers in the United States. It has a research partnership with the University of Mississippi to identify novel cannabinoids. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was incorporated in 2015 and is headquartered in Charlotte, North Carolina.

cbdMD, Inc.

CBDmd offers CBD products aimed at wellness and relief, self-described as providing high-quality solutions. The company specializes in a variety of CBD-infused products including drink mixers and gummies.

CBDmd

Cosmetics

cbdMD Botanicals

cbdMD | 9,548 followers on LinkedIn. At cbdMD, we combine premium quality and innovation to offer the purest CBD available on the market. We test our broad-spectrum CBD extractions through independent, third-party laboratories to guarantee the highest of standards. cbdMD is committed to providing the best in CBD; we stand behind the quality of our products by offering an easy-to-use service, free shipping, satisfaction guarantees, and US-based customer service.

Mortgage Loan Originator NMLS# 880611

Gregory Jones

CEO & CFO at cbdMD

Ronan Kennedy

Director of Procurement at cbdMD

Brad Trawick

Regulatory Paralegal at cbdMD

Catesha Alston

cbdMD

Consumers are increasingly interested in nutraceutical options for their health and wellness needs. They are looking to dietary supplements for non-pharmaceutical options to address areas including, mood, recovery, sleep, focus, memory, and immune support. The increased interest has led to a boom in the functional mushroom market which was estimated to be reach $32 billion in 2024 and is expected to hit almost $49 billion by 2029, which includes Lion’s mane mushroom, Chaga mushroom, Shiitake mushrooms, Reishi mushrooms, Cordyceps mushroom, Turkey tail mushrooms and Maitake mushrooms. A recent review explored the areas in which one functional mushroom, maitake, presents health benefits for consumers. The Maitake mushroom (Grifola frondosa) have been utilized for its adaptogenic and immune supporting properties for centuries. East Asian traditional medicine incorporates both the fruiting bodies and the mycelium into its practice for the numerous benefits it provides. Maitake mushrooms contain a multitude of bioactive substances including polysaccharides, beta-glucans, flavonoids, phenolic acids, ergosterol, dextrin, terpenoids, sterols, fatty acids, and oligofructose. Maitake’s rich polyphenol content has been associated with antioxidant activities, while their fatty acid and amino acid content present potential benefits for cosmetic products. It’s content of beta-glucans and other proteins have been linked to immune supporting potential. These constituents have also been linked to promotion of mediators of immune responses. More research is needed to fully appreciate the benefits this incredible mushroom. In recognition of Maitake’s benefits, our sister brand ATRx Labs, recently launched a line of platinum mushroom capsules, which includes the Everyday Immune: Wellness and Support capsules. ATRx Labs’ immune capsules include a blend of mushrooms to support immune function and overall wellness including Cordyceps, Reishi, Turkey Tail, Chaga, and Maitake. We will continue to share data on the benefits of functional mushrooms as it becomes available. #functionalnutrition #functionalmushrooms #innovation #researchanddevelopment https://lnkd.in/eSnt39xV

Nutrition Business Journal (NBJ) surveyed U.S. consumers who self-reported experiencing stress and other mood-related issues. The results indicated 55% of survey participants believe dietary supplements would have an impact on the mood-related issues. NBJ sales data for “Mood and Mental Health Supplements” demonstrated a significant increase in this category’s sales during the pandemic which continued to steadily grow post-pandemic, with predictions for total sales reaching an estimated $1.4 billion. The surge in interest for dietary supplements for mood-related issues has led to an increase in research for botanical ingredients addressing this area, including derivatives from Cannabis sativa L. Previously, most literature on efficacy pertaining to Cannabis sativa L. and benefits on mood issues was focused on cannabidiol (CBD) or tetrahydrocannabinol (THC). Despite the lack of data, consumers have reported using other minor phytocannabinoids, including cannabigerol (CBG), for mood-related conditions with success. CBG, often referred to as “the mother of all cannabinoids” because its acid form, cannabigerolic acid (CBGA), is the precursor for many other cannabinoids (including CBD and THC). A recent study in Nature Scientific Reports explored the acute effects of cannabigerol (CBG) for anxiety, stress, and mood. The study was a double-blind, placebo-controlled crossover field trial with a washout period between each testing session where participants consumed 20 mg of hemp-derived CBG or placebo tinctures one time before completing clinically verified assessments for depression, anxiety and stress. The data indicates a one-time consumption of 20 mg CBG resulted in significant reductions in subjects’ feelings of anxiety. In recognition of the benefits associated with consuming CBG, we have developed several products which incorporate it in the formula. We provide our customers with innovative products for their unique needs. We will continue to share information about CBG and other cannabinoids as it becomes available. #cannabinoids #CBG #botanicals #research #innovation #mentalhealth https://lnkd.in/gf9HbQDD

Anxiety disorders are ranked as the world’s most common mental disorders, affecting 4% of the global population or over 301 million people according to the World Health Organization (WHO). Anxiety manifests across several disorders including obsessive compulsive disorder (OCD), post-traumatic stress disorder (PTSD), social anxiety disorder (SAD), and generalized anxiety disorder (GAD). The symptoms often contribute to a reduced quality of life, increased unemployment rate, and a number of physical ailments. Treatment options range from psychological interventions to antidepressant medications. The medications typically present undesirable side effects and often leave persistent symptoms in a number of patients. Cannabidiol (CBD) has been studied in clinical trials for several indications, including anxiety disorders. A recent meta-analysis examined the effectiveness of CBD for anxiety disorders in open label and double-blind randomized clinical trials in published literature. The studies administered oral doses of CBD ranging from 25 mg up to 800 mg daily for durations of 110 minutes to 12 weeks to explore acute and chronic effects. Studies that provided participants with continuous doses of CBD demonstrated a significant improvement in anxiety. The overall conclusion of the meta-analysis was CBD does provide anxiolytic effects when consumed continuously (rather than a single acute dose) and the dose at which these effects occurred was 300 – 400 mg/day. Notably, CBD treatment demonstrated fewer side effects when compared to medical treatment for anxiety. cbdMD recently announced the results from our clinical trial in humans. We explored the effects of 100 mg CBD/day for a 90-day period in human subjects. Results included lower stress scores in female participants and a trend for lower tension/anxiety scores in both male and female participants. Our study provided lower doses of CBD than the study discussed today, which lends itself to the supplement-level endpoints we reported. Together, these studies add to the existing literature supporting the benefits of CBD for anxiety and other issues related to mental health. #CBDWellness #CBDBenefits #Research #Cannabinoids #Cannabidiol https://lnkd.in/eEUG6ts4

The NCAA Division I council voted last week to remove use of cannabis products from the banned drug class for championships and postseason participation in football will be effective immediately. This follows several professional leagues making the decision to remove bans on cannabinoid products. MLB made the decision to remove cannabis from the banned substance list and players are no longer tested. The NBA no longer tests athletes for cannabis or cannabinoid products. The NHL does test for cannabis, however, they do not punish players if they test positive. The UFC has also removed cannabis and cannabinoid products from its list of prohibited substances for athletes. The significant amount of data supporting the benefits of cannabidiol (CBD) and other cannabinoids from cannabis for recovery and overall mental wellness has contributed to the change in position by the NCAA and most professional sports leagues. “The NCAA drug testing program is intended to focus on integrity of competition, and cannabis products do not provide a competitive advantage,” NCAA Council Chairman, Josh Whitman said in a statement released by the NCAA following the decision. He went on to say, “The Council's focus is on policies centered on student-athlete health and well-being rather than punishment for cannabis use." At cbdMD, we understand the role cannabinoids, like CBD, play in recovery for athletes. cbdMD was the first CBD brand to offer three products with NSF’s Certified for Sport Certification. Our NSF Sport category offers a full suite of solutions for our customers including athletes, first responders, doctors, nurses, educators, tradespeople and anyone subject to a workplace drug test so they can focus on their mental health and recovery without fear of failing a drug test. For those without a concern about workplace or sports drug testing, cbdMD offers a line of full spectrum products ranging from microdose through high potency depending on the specific need. We’ve taken strides through our commitment to quality and science to offer products our customers can trust that are backed by rigorous studies. The results from our human clinical trial were published this week. They demonstrated our broad spectrum CBD, which is the core formula our NSF for Sports products were formulated with, has efficacy for pain. The study also indicated there may be mental health benefits as well: there was a trend for reduced “anger-hostility” for male subjects and a trend for lower “stress-anxiety” for female subjects following the consumption of 100 mg broad spectrum CBD. We will continue to share updates on cannabis or cannabinoid policy changes for sports leagues or data on the benefits of cannabinoids as it becomes available. #Recovery #Sportsnutrition #CBDbenefits #Research https://lnkd.in/gqpuKs3J

Sibyl Swift, Ph.D. , our Chief Science Officer, was featured in NutraIngredients-USA's article discussing cbdMD's human clinical study publication and how it will be incorporated into our messaging despite the lack of federal clarity. https://lnkd.in/eeS7nB4D

cbdMD Announces Publication of Human Clinical Trial Data We are pleased to announce the publication of the Company's human clinical trial data demonstrating the benefits of its proprietary Broad Spectrum CBD blend. The data was published in the Journal of the International Society of Sports Nutrition. The study confirms that in addition to demonstrating efficacy for pain, cbdMD's Broad Spectrum CBD is safe and well-tolerated, aligning with prior toxicity research that validates the safety of consuming 2.29 mg/kg of body weight daily. "This paper is a prime example of cbdMD's approach to science, which has laid the foundation for cbdMD to deliver safe, effective products formulated to specifically address the needs of our customers. We have proven cbdMD's products are safe and now we are showing our customers our commitment to efficacy in crucial areas such as pain management. When you seek a trustworthy product backed by science, look no further than cbdMD." said Ronan Kennedy , CEO and CFO. To view the complete published paper titled, "The effects of a brand-specific, hemp-derived cannabidiol product on physiological, biochemical, and psychometric outcomes in healthy adults: a double-blind, randomized clinical trial", please visit https://lnkd.in/esBtduxz . https://lnkd.in/eySdpUQb

Cordyceps militaris is an established ingredient in traditional Chinese medicine (TCM) due to its wealth of benefits. Cordyceps contains a wealth of beneficial constituents including polysaccharides, nucleotides, amino acids, cordycepic acid, ergosterol, and beta-sitosterol, which all contribute to its anti-inflammatory, antioxidant, neuroprotective, antiaging, and immune-supporting properties. Several human studies have been published that demonstrate cordyceps have immune-promoting and supporting effects, however, they lacked data on gender-specific effects. A recent study in Nature Scientific Reports explored the effects of cordyceps delivered in a beverage in a randomized controlled clinical trial on immune response in healthy male and female subjects. The data indicate cordyceps do activate immune-modulating cascades at different time points in male and female participants. Males demonstrated activation of natural killer cells after four weeks and females exhibited significant activation after eight weeks of supplementation with the cordyceps beverage. Males also exhibited an increase in monocyte levels after four and eight weeks of consuming the cordyceps beverage, however the increase was within normal ranges. Male subjects showed an increase in IL-1b at four weeks and female subjects had higher IL-6 levels after eight weeks. Overall, this study supports the immune-modulating benefits of cordyceps in male and female subjects. cbdMD’s sister brand, ATRx Labs, launched the Ultimate Mushroom gummies in recognition of the benefits of functional mushrooms, like cordyceps, lion’s mane, and reishi for a number of areas, including the immune benefits described in the article today. We anticipate future additions to the functional mushroom line in ATRx Labs in recognition of the growing body of literature supporting their benefits. We will continue to share data on the benefits of functional mushrooms and other botanical ingredients as it becomes available. https://lnkd.in/eGfeEjjf #functionalnutrition #functionalmushrooms #innovation #researchanddevelopment

Mental health disorder is a broad term, covering a number of areas including anxiety, depression, post-traumatic stress disorder, and others. These disorders impact cognition, emotion, behavior and impair functioning. The World Health Organization (WHO) estimates that 1 in every 8 people (approximately 970 million) around the world suffer from a mental disorder, with anxiety and depression at the top of the list as most prevalent. WHO also estimated approximately 301 million people were living with an anxiety disorder and was increasing by 26% each year. Many of the current pharmaceutical treatment options have low efficacy rates, cause other symptoms, and potentially lead to adverse events. As the awareness of mental health issues has increased, particularly anxiety, so have the options for treatment, including alternatives to the traditional pharmaceutical recommendations. Cannabidiol (CBD) is a well-studied, nonpsychoactive phytocannabinoids that has demonstrated efficacy for mental disorders, including anxiety. A recent study explored the efficacy of CBD in a double-blind, multicenter, randomized clinical trial for participants with mild to moderate anxiety. Participants in the treatment group received CBD in doses which incrementally increased over the first three weeks of the study from 300 mg/day up to the full quantity of 600 mg/day. The doses were sustained at 600 mg/day until the last week of the study when they were tapered back to 150 mg/day. Subjects in the CBD group demonstrated significant improvements in GAD-7 and HAM-A scores, which are validated tests for anxiety disorder. Subjects in the CBD treatment group also demonstrated significant improvements in all secondary measures which were assessed with clinically validated tests including Clinical Global Impression-Improvement (CGI-I), Clinical Global Impression-Severity (CGI-S), Patient’s Health Questionnaire-9 (PHQ-9), and Pittsburgh Sleep Quality Index (PSQI). cbdMD completed a human double-blind, single-center, randomized clinical study which provided healthy study participants with 100 mg/CBD daily for 90 days. Female participants in the CBD treatment group reported less stress in comparison to the placebo group. Our study provided lower doses of CBD than the study discussed today, which lends itself to the supplement-level endpoints we reported. Together, these studies add to the existing literature supporting the benefits of CBD for anxiety and other issues related to mental health. #CBDWellness #CBDBenefits #Research #Cannabinoids #Cannabidiol https://lnkd.in/erxqjqYR

Osteoarthritis is a well-known condition which significantly impacts synovial joint cartilage and therefore the quality of life in those affected. It is estimated that osteoarthritis of the hand effects approximately 44% of women and 38% of men with symptoms including pain, stiffness, inflammation and loss of strength. Treatment options focus on symptoms and typically include non-steroidal anti-inflammatory drugs (NSAIDs) as topical medication. If topical options are insufficient, oral NSAIDs are then recommended, however, theuy are known to cause negative gastrointestinal and renal effects. Consumers are seeking botanically-derived options for pain and inflammation that are not pharmaceutical to avoid the side effects associated with this type of treatment. Cannabidiol (CBD) from hemp has been identified as potentially efficacious as an oral or topical analgesic or anti-inflammatory option. Topical formulations with CBD have demonstrated efficacy in several studies, including a study of retired athletes with lower limb pain from injuries and in several preclinical studies. A study published in Nature Research Scientific Reports explored the effects of transdermal CBD in a single-center, interventional, feasibility trial on hand pain, grip strength, and hand functionality. Participants applied the transdermal cream (10 mg CBD) to their most painful hand three times daily for four weeks. Administration of CBD through transdermal application effectively reduced hand pain and grip strength compared to baseline measures. There was also significant improvement in quality of life indices including anxiety, stiffness, and fatigue. CBD delivery was systemic due to the transdermal application, which was confirmed through analysis of urinary concentrations of CBD and several metabolites. The data from this study supports the growing body of literature that intake or administration of CBD helps to reduce pain and provides anti-inflammatory benefits. cbdMD has completed two clinical studies exploring the benefits of our broad spectrum extract on a number of endpoints, including pain. The human clinical provided study participants with 100 mg CBD daily for 90 days, which yielded data supporting our broad spectrum extract’s benefits for daily pain. The canine clinical study administered 5 mg CBD per kg bodyweight to dogs over a 45 day period and found significant reductions in pain severity and pain interference scores in the CBD group. Additionally, canine subjects demonstrated clinically relevant improvements in quality of life and activity scores following CBD consumption. While the route of administration differs, there is a growing body of literature supporting CBD’s benefit on areas which impact quality of life, like pain. We will continue to share data on the benefits of cannabinoids and other functional ingredients as it becomes available. #CBDBenefits #CBDWellness #Research #Cannabinoids https://lnkd.in/enHREW2S

Post-traumatic stress disorder (PTSD) is recognized in the Diagnostic and Statistical Manual of Mental Disorders (DSM V). It typically occurs following a traumatic event (or events) with resultant symptoms including sleep disruption, heightened fear responses, and anxiety among others. As the term PTSD has become more prevalent the options for treatment have also increased with varying degrees of success. Psychotherapy treatments have mixed results in PTSD patients. Pharmacological solutions typically begin with selective serotonin reuptake inhibitors (SSRIs) but have a lower rate of success than psychotherapy treatments. Pharmaceutical options that are most promising target receptors including N-methyl-D-aspartic acid receptor, 5HT2 receptor, and CB1 receptor. CB1 receptors in the brain are associated with memory extinction, a critical step in the treatment of PTSD. ∆9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are well-studied cannabinoids extracted from Cannabis sativa L., which are both known to interact with the CB receptors. A review published in The Journal for Basic Clinical Physiology and Pharmacology analyzed studies exploring the efficacy of cannabinoids for human subjects with PTSD. The results of the review indicate cannabinoids (CBD or THC) are effective at addressing PTSD symptoms including reducing daytime flashbacks, decreasing hyperarousal, increasing sleep quality and general wellbeing. More studies are needed to confirm the results, however, the data covered in this review is encouraging for anyone impacted by PTSD. At cbdMD, we recognize the importance of providing our customers with products that address their needs. Our suite of products provides broad spectrum (no THC) or full spectrum (with THC) options for the areas which matter most, including sleep, mood, and others. We will continue to share data on the benefits of cannabinoids and other functional ingredients as it becomes available. #CBDBenefits #CBDWellness #Research #Cannabinoids https://lnkd.in/e6QjwFkw

	Sep '16	Sep '17	Sep '18	Sep '19	Sep '20	Sep '21	Sep '22	Sep '23
net income	-3.90M -	-1.39M 64.42%	62.83K 104.53%	-51.36M 81,835.29%	12.60M 124.54%	-23.39M 285.64%	-70.08M 199.57%	-22.94M 67.27%
depreciation and amortization	44.94K -	71.28K 58.62%	222.55K 212.23%	289.57K 30.12%	720.75K 148.90%	2.25M 212.70%	2.97M 31.80%	2.93M 1.44%
deferred income tax		296.23K -	571.65K 92.98%	6.79M 1,087.18%	1.21M 82.15%	-471.02K 138.89%		14.98M -
stock based compensation	11.45K -	212.93K 1,759.68%	678.73K 218.75%	2.69M 296.11%	2.04M 24.19%	2.92M 43.50%	928.83K 68.24%	342.87K 63.09%
change in working capital	673.88K -	-988.43K 246.68%	-4.20M 325.00%	-6.07M 44.40%	-184.51K 96.96%	-2.82M 1,430.67%	-2.77M 1.87%	570.45K 120.58%
accounts receivables	-163.82K -	-789.99K 382.22%	-991.95K 25.56%	-401.98K 59.48%	514.35K 227.95%	-183.74K 135.72%	65.54K 135.67%	278.48K 324.90%
inventory	-519.74K -	-41.22K 92.07%	255.89K 720.86%	-3.12M 1,320.60%	-535.15K 82.87%	-1.01M 88.58%	-112.19K 88.88%	27.44K 124.46%
accounts payables	785.92K -	-466.99K 159.42%	-666.67K 42.76%	394.32K 159.15%	1.48M 275.13%	-740.07K 150.03%	-1.81M 144.92%	61.18K 103.38%
other working capital	571.53K -	309.76K 45.80%	-2.80M 1,003.31%	-2.93M 4.89%	-1.64M 44.02%	-891.28K 45.75%	-912.36K 2.37%	203.34K 122.29%
other non cash items	268.75K -	-239.45K 189.10%	-2.91M 1,114.44%	32.28M 1,210.09%	-27.05M 183.80%	7.42M 127.42%	53.99M 627.79%	-184.26K 100.34%
net cash provided by operating activities	-2.90M -	-2.33M 19.58%	-5.57M 139.20%	-15.38M 175.92%	-10.66M 30.65%	-14.09M 32.15%	-14.97M 6.20%	-4.30M 71.26%
investments in property plant and equipment	-127.26K -	-7.97K 93.74%	-383.56K 4,714.35%	-1.25M 225.53%	-1.32M 5.72%	-2.34M 77.41%	-688.68K 70.59%	-297.55K 56.79%
acquisitions net				-916.55K -		2M -
purchases of investments			-300K -		-250K -	-750K 200%
sales maturities of investments		200K -				540K -		1M -
other investing activites		-39.72K -		31.32K -		-2M -
net cash used for investing activites	-127.26K -	152.31K 219.69%	-683.56K 548.79%	-2.13M 212.17%	-1.57M 26.42%	-2.55M 62.54%	-688.68K 73.01%	702.45K 202.00%
debt repayment	-1.26M -	-300K 76.10%		-764.30K -	-1.49M 94.39%	-151.55K 89.80%	-33.35K 77.99%	-132.60K 297.54%
common stock issued	1.98M -	829.50K 58.21%	10.93M 1,217.37%	19.01M 73.96%	16.77M 11.80%	30.94M 84.53%		2.48M -
common stock repurchased					-1.49M -	-30.79M 1,972.17%		132.60K -
dividends paid					-366.85K -	-2.55M 596.36%	-4.00M 56.66%	-3.67M 8.33%
other financing activites	1.78M -	1.90M 6.46%	-672.57K 135.44%	-326.87K 51.40%	8.94M 2,835.45%	30.79M 244.32%		-132.60K -
net cash used provided by financing activities	2.51M -	2.43M 3.38%	10.25M 322.45%	17.92M 74.73%	22.37M 24.84%	28.23M 26.21%	-4.04M 114.29%	-1.32M 67.22%
effect of forex changes on cash				1 -	-1 200%
net change in cash	-512.20K -	249.99K 148.81%	4.00M 1,499.40%	407.41K 89.81%	10.13M 2,387.57%	11.59M 14.33%	-19.69M 269.95%	-4.92M 75.00%
cash at beginning of period	546.46K -	34.26K 93.73%	284.25K 729.72%	4.28M 1,406.64%	4.69M 9.51%	14.82M 216.09%	26.41M 78.16%	6.72M 74.56%
cash at end of period	34.26K -	284.25K 729.72%	4.28M 1,406.64%	4.69M 9.51%	14.82M 216.09%	26.41M 78.16%	6.72M 74.56%	1.80M 73.25%
operating cash flow	-2.90M -	-2.33M 19.58%	-5.57M 139.20%	-15.38M 175.92%	-10.66M 30.65%	-14.09M 32.15%	-14.97M 6.20%	-4.30M 71.26%
capital expenditure	-127.26K -	-7.97K 93.74%	-383.56K 4,714.35%	-1.25M 225.53%	-1.32M 5.72%	-2.34M 77.41%	-688.68K 70.59%	-297.55K 56.79%
free cash flow	-3.02M -	-2.34M 22.70%	-5.96M 154.80%	-16.63M 179.12%	-11.98M 27.92%	-16.44M 37.14%	-15.66M 4.74%	-4.60M 70.62%

COM:CBDMD

CBDmd

Last Close

0.46

22/11 20:59

Market Cap

2.16M

Beta: -

Volume Today

45.00K

Avg: -

Preview